Investor Relations (IR) Questions: Dyax Corp DYAX
Answers received: February 2013
1) When is the last time DYAX raised cash through an offering (diluted)?
The last time Dyax raised cash through a dilutive offering was in March 2010.
2) How much cash (not cash equivalents) does DYAX have?
As reported in our Fourth Quarter and Year End 2012 earnings call and press release, our cash resources as of December 31st 2012 were $29 million.
3) What and approximately when is the next known catalyst?
The next known catalyst will be Dyax’s first quarter 2013 earnings results to be reported the last week of April 2013.
4) What is DYAX's quarterly cash burn?
As reported in our Fourth Quarter and Year End 2012 earnings call and press release Dyax’s quarterly cash burn was $3.5 million.
5) Does DYAX have an existing line of credit and if so how much can they draw against it?
No, Dyax does not currently have an existing line of credit.
1) When is the last time DYAX raised cash through an offering (diluted)?
The last time Dyax raised cash through a dilutive offering was in March 2010.
2) How much cash (not cash equivalents) does DYAX have?
As reported in our Fourth Quarter and Year End 2012 earnings call and press release, our cash resources as of December 31st 2012 were $29 million.
3) What and approximately when is the next known catalyst?
The next known catalyst will be Dyax’s first quarter 2013 earnings results to be reported the last week of April 2013.
4) What is DYAX's quarterly cash burn?
As reported in our Fourth Quarter and Year End 2012 earnings call and press release Dyax’s quarterly cash burn was $3.5 million.
5) Does DYAX have an existing line of credit and if so how much can they draw against it?
No, Dyax does not currently have an existing line of credit.
Click here to return to the biotech IRQ Index
Answers received: September 2012
1) When is the last time DYAX raised cash through an offering (diluted)? March 2010
2) How much cash (not cash equivalents) does DYAX have? Dyax reported $38.6M in cash at the end of 2Q12.
3) What and approximately when is the next known catalyst?
I’m not sure what you consider catalysts but our near-term milestones are:
· 3Q12 earnings which will be at the end of October
· 1H13:
o Potential IND filing for DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein, that has the potential for less frequent dosing and therefore may be an appropriate candidate for a prophylactic, subcutaneous formulation
o Begin clinical validation of a laboratory test which will be used to help identify patients that have plasma kallikrein (bradykinin) mediated angioedema
· 1H13 through 1H15:
o Potential data read-outs from our licensing partner Eli Lilly/ImClone in regards to their compounds Ramucirumab and Necitumab
· Projected cash flow break-even during 2013
4) What is DYAX's quarterly cash burn? In 2Q12, Dyax’s cash burn was $7M. This is down from $8.5M in 1Q12.
5) Does DYAX have an existing line of credit and if so how much can they draw against it? Dyax does not have an existing line of credit.
1) When is the last time DYAX raised cash through an offering (diluted)? March 2010
2) How much cash (not cash equivalents) does DYAX have? Dyax reported $38.6M in cash at the end of 2Q12.
3) What and approximately when is the next known catalyst?
I’m not sure what you consider catalysts but our near-term milestones are:
· 3Q12 earnings which will be at the end of October
· 1H13:
o Potential IND filing for DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein, that has the potential for less frequent dosing and therefore may be an appropriate candidate for a prophylactic, subcutaneous formulation
o Begin clinical validation of a laboratory test which will be used to help identify patients that have plasma kallikrein (bradykinin) mediated angioedema
· 1H13 through 1H15:
o Potential data read-outs from our licensing partner Eli Lilly/ImClone in regards to their compounds Ramucirumab and Necitumab
· Projected cash flow break-even during 2013
4) What is DYAX's quarterly cash burn? In 2Q12, Dyax’s cash burn was $7M. This is down from $8.5M in 1Q12.
5) Does DYAX have an existing line of credit and if so how much can they draw against it? Dyax does not have an existing line of credit.
